Labcorp's Q2 Earnings Beat Estimates, Raises Full-Year Guidance

Labcorp Holdings reported Q2 earnings that beat analyst expectations, with a 9.5% YoY revenue increase to $3.53 billion. The company raised its full-year guidance, projecting adjusted EPS between $16.05 and $16.50 and revenue growth between 7.5% and 8.6%. Shares jumped 6.8%, setting a new 52-week high and increasing the investment value for shareholders since the beginning of the year.

Title: Labcorp Holdings Reports Strong Q2 Earnings and Raises 2025 Outlook

Labcorp Holdings (NYSE: LH) reported its second-quarter (Q2) earnings, which exceeded analyst expectations. The company reported adjusted earnings per share (EPS) of $4.35, a 10.4% year-over-year (YoY) increase, surpassing the Zacks Consensus Estimate by 5.07% [1]. The company's revenue for the quarter rose 9.5% YoY to $3.53 billion, beating the Zacks Consensus Estimate by 1.14% [1].

The revenue growth was driven by organic revenue growth of 5.4%, acquisitions (net of divestitures) of 3.5%, and a foreign currency translation gain of 0.6% [1]. The Diagnostics Laboratories segment reported revenues of $2.75 billion, an 8.9% YoY increase, while the Biopharma Laboratory Services segment saw revenues rise 11% to $784.8 million [1]. Labcorp's gross margin expanded by 90 basis points (bps) to 29.7%, despite an 8.1% rise in the cost of revenues [1].

Following the earnings announcement, Labcorp shares jumped 6.8%, setting a new 52-week high and increasing the investment value for shareholders since the beginning of the year [2]. The company also raised its 2025 outlook, projecting adjusted EPS between $16.05 and $16.50 and revenue growth between 7.5% and 8.6% [1]. The Zacks Consensus Estimate for full-year revenues is pegged at $13.91 billion [1].

Labcorp's performance was driven by strong organic growth and strategic initiatives, such as the expansion of its oncology portfolio and consumer-initiated tests through the Labcorp OnDemand platform [1]. The company also expanded its partnerships with hospitals, health systems, and regional or local labs, improving access to comprehensive testing and laboratory services [1].

Investors should closely monitor Labcorp's execution of its strategic initiatives and the impact of currency fluctuations on its financial performance. The company's Zacks Rank is currently #3 (Hold), but it is outperforming some better-ranked stocks in the broader medical space, such as Intuitive Surgical (ISRG), Veeva Systems (VEEV), and Resmed (RMD) [1].

References
[1] https://finance.yahoo.com/news/labcorp-q2-earnings-revenues-beat-144900107.html
[2] https://finance.yahoo.com/news/labcorp-lh-shares-skyrocket-know-165558088.html